Increased plasma thrombomodulin in cancer patients

Area of Science:

• Oncology
• Hematology
• Biochemistry

Background:

• Soluble plasma thrombomodulin (TM) is an endothelial cell marker.
• Elevated TM levels have been observed in various conditions, but its role in different cancer types requires further investigation.

Purpose of the Study:

• To investigate soluble plasma thrombomodulin (TM) levels in patients with colorectal cancer, pancreatic cancer, and terminal-stage cancers.
• To assess the correlation between TM levels and cancer progression and other coagulation inhibitors.

Main Methods:

• Plasma samples were analyzed using an ELISA method to quantify soluble plasma thrombomodulin (TM).
• Patients included those with colorectal cancer, pancreatic cancer, and various terminal-stage cancers.
• Levels were compared to healthy controls and correlated with disease stage and tissue factor pathway inhibitor (TFPI).

Main Results:

• Colorectal cancer patients had normal TM levels at diagnosis, but levels increased with disseminated disease.
• Pancreatic cancer patients exhibited elevated TM levels at diagnosis, which further increased with disease progression.
• Patients with terminal-stage cancers showed significantly increased mean TM levels compared to controls.
• No significant correlation was found between TM levels and tissue factor pathway inhibitor (TFPI) levels.

Conclusions:

• Plasma TM levels show potential as a biomarker for cancer progression, particularly in pancreatic and disseminated colorectal cancers.
• Elevated TM levels in advanced cancers suggest distinct underlying mechanisms compared to TFPI.
• Further research is warranted to explore the diagnostic and prognostic value of TM in oncology.